Effect Of Denosumab Vs Risedronate In Glucocorticoid Induced Osteoporosis

Synopsis  A clinical study demonstrates that Denosumab is more efficacious and well tolerated treatment option as compared to Risedronate for patients, newly initiating or continuing glucocorticoids and are at risk of fractures. This week's ' MED FACT ' discusses a clinical trial from Lancet Diabetes & Endocrinology , “ Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study ”. Apr 2018.

Authors : Saag KG; Wagman RB; Geusens P; Adachi JD; Messina OD; Emkey R; Chapurlat R; Wang A; Pannacciulli N; Lems WF. Key Takeaways Denosumab is an effective and well tolerated treatment in glucocorticoid-induced osteoporosis. Objective Study Type Participants To analyse the effect of denosumab vs risedronate in glucocorticoid-induced osteoporosis Randomised, double blind, double-dummy,…